Table 3 LLACS according to FibroTest® categories
Characteristic | Total | FibroTest® stages | p value for trend | |||
|---|---|---|---|---|---|---|
F0 | F1 | F2 | F3-F4 | |||
All patients | ||||||
Participants, n (%) | 150 | 59 (39%) | 41 (27%) | 21 (14%) | 29 (19%) | Â |
LLACS at baseline, AU | 503 [44 to 2224] | 181 [0 to 1449] | 434 [102 to 2311] | 923 [349 to 2196] | 1199 [287 to 3998] | 0.050 |
LLACS at the end of follow-up, AU | 1242 [132 to 4112] | 421 [20 to 3382] | 1298 [95 to 4169] | 1462 [609 to 3275] | 2707 [845 to 7400] | 0.042 |
Absolute change in LLACS, AU | 547 [53 to 1761] | 243 [14 to 881] | 685 [49 to 2037] | 644 [311 to 1650] | 1424 [427 to 3858] | 0.030 |
Annualized change in LLACS, AU/year | 215 [21 to 688] | 90 [5.4 to 382] | 291 [19 to 781] | 248 [125 to 633] | 465 [140 to 1674] | 0.023 |
Patients with no progression of LLACS | ||||||
Participants, n (%) | 23 | 13 (57%) | 8 (35%) | 0 (0%) | 2 (9%) | 0.037 |